AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$AMGN

57 ETFs Add to Amgen (AMGN) Holdings on Wednesday

Amgen (AMGN) saw $79.8M net inflows from ETFs on Wednesday, extending a four-day buying streak. Top buyers included DIA ($49.7M), XLV ($10.7M), and IBB ($8.4M). AMGN's market cap is $248.8B, with YTD gains of 43.5%. Revenue grew 8.1% YoY to $38.98B, with a 24.1% net margin. The stock trades at a P/E of 26.7.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
57 ETFs Add to Amgen (AMGN) Holdings on Wednesday — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AMGNNeutralLow
01

Why it matters

ETF inflows of $79.8 million suggest modest buying pressure but are unlikely to move the stock significantly on their own.

02

Market read

ETF buying provides a small bullish signal for AMGN but does not constitute a major catalyst.

03

What to watch

Potential upcoming earnings or pipeline news could amplify or reverse the effect.

Relevance 4/10Novelty 3/10Timing: today

Background

Amgen is a large biotech firm with a market cap of ~$249 billion; ETF activity is a common driver of short‑term price moves.

Company-level read

Ticker impact

$AMGNNeutralMedium confidence
Context

ETFs added a net $79.8 million of shares to Amgen (AMGN) on Wednesday, extending a four‑day buying streak.

Expected impact

likely modest upside as inflows support the share price

Evidence & confidence

Large ETF purchases increase demand and can lift the stock, but the amount is modest relative to market cap.

Market effects

Sector

ETF buying reflects continued investor interest in the healthcare sector, but no broader sector shift is indicated.

Regional

U.S. market participants may see slight uplift in biotech exposure.

Global

Limited to U.S. investors; no global impact.

Counterpoint

What could challenge this read

The inflow could be a short‑cover rally rather than a sustainable buying trend.

Key entities

  • company
    Amgen Inc.

    Biotech company receiving ETF inflows.

Read at source← All news

Related articles

$AMGNMed

Freedom Broker downgrades Amgen stock rating on valuation despite raising price target

Freedom Broker downgraded Amgen (AMGN) to Hold from Buy, raising its price target to $470. The move follows strong quarterly results, with revenue and EPS beating expectations. Amgen raised its full-year guidance, and shares are up 44% year-to-date. Analysts cite strong performance but note the stock is near fair value. Other analysts, including UBS and RBC, raised their price targets.

investing.com
$AMGNLow

FDA Approval for AMJEVITA issued to AMGEN INC

The FDA approved a label update for Amgen's AMJEVITA (adalimumab-atto) on 11/05/2026, according to the company. The approval covers the 20 mg/0.4 mL and 40 mg/0.8 mL injectable products, but no new indication was disclosed. This is a routine regulatory update for an already approved product.

quantisnow.com
$AMGNMed

Amgen’s Repatha reduces heart attack risk in real-world study

Amgen's Repatha (evolocumab) reduced heart attack risk by 20% compared to ezetimibe in a real-world study of 544,103 adults with atherosclerotic cardiovascular disease, according to the company. The four-year study tracked patients from 2017 to 2024, with Repatha showing a lower cumulative incidence of heart attacks (5.88% vs. 7.76%). Amgen's chief medical officer highlighted the study's relevance for treatment decisions.

clinicaltrialsarena.com